Novo Nordisk Shares Plunge to Multi-Year Low Amid Regulatory and Clinical Setbacks
Published on 11/28/2025 at 11:53 | Redaktion boerse-global.de
Novo Nordisk’s stock has entered a dramatic downturn, shedding more than half its value since the start of the year and currently trading at its lowest point in four years. Panicked investors are exiting their positions following a series of negative developments, though a surprise fast-track application to the U.S. Food and Drug Administration offers a potential lifeline. The critical question for the market is whether the severe sell-off represents an overreaction or signals deeper troubles ahead for the pharmaceutical giant.
In a strategic countermove, Novo Nordisk’s management has submitted an urgent application to the FDA seeking approval for a new, higher-dose 7.2 mg version of its weight-loss injection, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
